Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial

Table 4

Safety outcomes.

Variable	Naloxegol, n = 6	Placebo, n = 6	value
Patients with ≥1 episode of diarrhea, N (%)	4 (67)	4 (67)	>0.99
Time to first episode, hours, median (IQR)	40 (19, 66)	109 (48, 169)	0.57
Resolution of diarrhea within 24 hours after holding study drug and laxative protocol is stopped, N (%)	2 (50)	2 (50)	>0.99
Persistence of diarrhea ≥48 hours after study drug is held and laxative protocol is stopped, N (%)	2 (50)	2 (50)	>0.99
Use of a rectal tube, N (%)	3 (75)	1 (25)	0.54
Clinical opioid withdrawal scale	−0.1 ± 1.3	+0.2 ± 1.3	0.31
Difference in predose and postdose scores, mean ± SD

IQR: interquartile range; N: number; SD: standard deviation.